GILD - Gilead Sciences: Some Signs Of An Impending Bottom
2024-04-22 12:03:00 ET
Summary
- The stock of Gilead Sciences, Inc. has underperformed the market substantially over the past decade, but there are some signs developing of a potential bottom.
- The stock offers a high dividend yield of 4.61% and is trading at a low valuation compared to its peers.
- Gilead is a leader in the HIV space, and its oncology revenues are growing rapidly. The company also has a large pipeline and recently acquired CymaBay Therapeutics.
- An analysis of Gilead Sciences follows in the paragraphs below.
Today, we put Gilead Sciences, Inc. ( GILD ) in the spotlight for the first time in years. As can be seen in the chart below, the stock has done little for its shareholders over the past decade....
Gilead Sciences: Some Signs Of An Impending Bottom